More physicians are using AI for clinical search, pushing tech companies to compete on speed, medical sourcing, and trust.
With insurers declining to participate in GLP-1 coverage, Medicare will now subsidize the drugs, though concerns around muscle loss may temper prescribing.
RFK Jr. backs voluntary limits for food marketing, aligning unhealthy food with pharma in Washington’s broader crackdown on health-linked marketing.
The anti-aging market isn’t fueled by broad, mass adoption. In reality, only about 10% of US consumers actively prioritize preventing signs of aging, according to YouGov’s 2026 Anti-aging report.
Amazon aims to turn GLP-1 demand into a funnel for One Medical, though limiting new prescriptions to members softens the competitive threat to other telehealth players.
By cutting unprofitable members to restore margins and investing in AI to boost efficiency, UnitedHealth’s strategy offers insurers a 2026 survival guide.
Many self-diagnosers skip seeing a provider—raising the stakes for pharma brands to better connect patients with doctors.
Its Kelonia acquisition, alongside neurology and immunology moves, makes a more sustainable drug pipeline beyond its blockbuster GLP-1s.
The drugs will get expedited FDA review and expanded patient access as soon as summertime amid rising consumer interest and clinician caution.
The $625 million raise signals Wall Street’s conviction in durable GLP-1 weight loss drug demand even as more players crowd the field.
Nearly half delay or skip doctor visits, turning to over-the-counter and at-home remedies to save money.
Health plans reduced prior authorizations by 11%, but pressure on insurers remains as the changes risk seeming cosmetic without clear impact on clinicians and patients.
Failing to obtain consent when using AI scribes during medical appointments breaches trust, damages reputations, and risks driving patients away.
Consumers are increasingly turning to AI to overcome cost and access barriers. But because its health advice can be unreliable, provider organizations should guide safe use and offer their own vetted chatbots.
As Medicare GLP-1 coverage begins, Walmart can capture more weight-care demand from its boomer customer base.
Drug brands invested $1.6B in linear, down 8% QoQ, while NFL and Olympics broadcasts dominated total spending.
A new partnership between Novo Nordisk and OpenAI underscores pharma’s urgency to harness AI for quicker cures.
A recent Pfizer warning shows that regulators are leaning into policing Facebook ads as closely as TV commercials.
Younger consumers respond to GLP-1 ads, but increasing ad spend risks fatigue, making sharper creative and more point-of-care marketing increasingly important.
They start health condition and treatment queries via search engines most often, but rely on journals to verify information, revealing a gap between use and credibility.